DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Mallinckrodt plc (" Mallinckrodt " or the "Company"), a global specialty pharmaceutical company, today announced that it will report third quarter 2024 earnings results for the period ended September 27, 2024, on Tuesday, November 5 , 2024. A conference call for investors will begin at 8:30 a.
m. ET . The call can be accessed as follows: Live Call Participant Registration (including dial-in): https://register.
vevent.com/register/BI60bb36abdb99465c9db5640f3457528a Audio Only Webcast Link (live and replay): https://edge.media-server.
com/mmc/p/6tqaksqg/ At the Mallinckrodt website: https://ir.mallinckrodt.com/ ABOUT MALLINCKRODT Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies.
The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt , visit www.
mallinckrodt.com . Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and .